JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 22 No. 10 880-883
© 1981 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fogelman, I.
Right arrow Articles by Francis, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fogelman, I.
Right arrow Articles by Francis, M. D.

A Comparison of Skeletal Uptakes of Three Diphosphonates by Whole-Body Retention: Concise Communication

I. Fogelman, D. W. Pearson, R. G. Bessent, A. J. Tofe and M. D. Francis

Glasgow Royal Infirmary, Glasgow, Scotland
Miami Valley Laboratories, Procter & Gamble Company, Cincinnati, Ohio

Correspondence: For reprints contact: Ignac Fogelman, University Departments of Medicine and Nuclear Medicine, Royal Infirmary, Glasgow, G4 OSF, Scotland.

ABSTRACT

Twenty normal volunteers had measurements of 24-hr whole-body retention (WBR) of three structurally related Tc-99m-labeled phosphonate skeletal imaging agents: (1-hydroxyethylidene) diphosphonate (HEDP), methylene diphosphonate (MDP), and hydroxymethylene diphosphonate (HMDP). The average WBR values, reflecting skeletal uptake, were 18.4, 30.3, and 36.6%, respectively. These results clearly illustrate that slight alterations in diphosphonate molecular structure have a significant effect upon specificity for osseous tissue, and thus may affect skeletal image quality and the usefulness of the WBR technique in diagnosing metabolic bone disease.




This article has been cited by other articles:


Home page
JNMHome page
J. G. Rajendran, J. F. Eary, W. Bensinger, L. D. Durack, C. Vernon, and A. Fritzberg
High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation
J. Nucl. Med., October 1, 2002; 43(10): 1383 - 1390.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1981 by the Society of Nuclear Medicine.